Dyne Therapeutics (NASDAQ:DYN) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Dyne Therapeutics (NASDAQ:DYN) posted its quarterly earnings data on Tuesday. The company reported ($0.88) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.04, Zacks reports.

Dyne Therapeutics Trading Down 3.5 %

Shares of Dyne Therapeutics stock opened at $11.89 on Wednesday. The firm has a market capitalization of $1.21 billion, a P/E ratio of -3.34 and a beta of 1.11. The business has a fifty day simple moving average of $16.75 and a two-hundred day simple moving average of $27.26. Dyne Therapeutics has a 12 month low of $11.62 and a 12 month high of $47.45.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Guggenheim restated a “buy” rating on shares of Dyne Therapeutics in a research report on Friday, January 24th. Chardan Capital reissued a “buy” rating and set a $50.00 price objective on shares of Dyne Therapeutics in a research note on Friday, February 28th. Baird R W raised Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday, December 12th. Robert W. Baird started coverage on Dyne Therapeutics in a research note on Friday, December 13th. They set an “outperform” rating and a $46.00 price objective for the company. Finally, HC Wainwright dropped their price objective on Dyne Therapeutics from $55.00 to $46.00 and set a “buy” rating for the company in a research note on Friday, February 28th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, ten have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $48.64.

Insider Buying and Selling at Dyne Therapeutics

In other news, SVP Richard William Scalzo sold 1,455 shares of the firm’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total transaction of $40,914.60. Following the completion of the transaction, the senior vice president now directly owns 127,078 shares in the company, valued at $3,573,433.36. This trade represents a 1.13 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Oxana Beskrovnaya sold 2,334 shares of the firm’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total value of $65,632.08. Following the transaction, the insider now owns 201,685 shares of the company’s stock, valued at $5,671,382.20. The trade was a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 6,387 shares of company stock valued at $142,789. 20.77% of the stock is currently owned by company insiders.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.